Print

Print


University of California, San Francisco Stem Cell Research Receiving a Groundswell of Financial Support from Private
Philanthropists
Tuesday October 14, 7:41 am ET

SAN FRANCISCO, Oct. 14 /PRNewswire/ -- Since President Bush's announcement in August 2001 limiting federal funding of
Stem Cell research, leading research institutions have turned to private funding to retain the best research talent and
keep pace with research progress. And many private citizens are heeding the call. "Without private support, this
nation's leading researchers are drawn to continue their research elsewhere," says Dr. Jeffrey Bluestone, University of
California, San Francisco (UCSF), Interim Director of the Developmental and Stem Cell Biology Program. Since the Bush
announcement, UCSF lost one of its leading Stem Cell researchers, Dr. Roger Pedersen to Cambridge University in
England, where public funding for stem cell research is more generous and far less restricted.

Fueled by the goal to keep the world's leading researchers and their breakthrough discoveries here in the U.S., private
donations are on the rise. The Stem Cell Biology Program at UCSF has recently received grant support from Mr. Mouli
Cohen to help launch an FDA-approved "core research facility," a key component in translating the laboratory
advancements made in stem cell research into therapeutic applications. Mr. Cohen's contribution is targeted to move the
FDA Approved facility into self-sufficiency within the year and represents an entrepreneurial approach to funding that
incorporates a business plan approach to stem cell research.

"The stem cell research being conducted at UCSF is producing breakthroughs with tremendous potential for practical
therapeutic applications," explains Mr. Cohen. "The most responsible kind of philanthropy we can provide is to help
fund the support and translation facilities that will speed the most promising breakthroughs from the laboratory bench
into clinical human trials."

Current studies at UCSF involve both animal and human stem cells and are paving the way for treatments of various
diseases and conditions, such as diabetes, cardiovascular disease, Parkinson's disease, Alzheimer's disease and spinal
cord injury. One such study, conducted by Didier Stainier, PhD, has discovered a "master" gene for myocardial, or heart
muscle, cells in zebrafish. If human heart cells have a similar gene, it may hold the key for a human embryonic stem
cell to become a beating heart cell. Therapeutic control of this master gene could allow researchers to cultivate and
harvest such myocardial cells then transplant them into people with failing hearts.

Susan Fisher, PhD, another researcher at UCSF, is developing new methods critical to enable laboratory research to
progress into human clinical trials. Her lab has shown that stem cells can be cultivated in a system that uses human
cells exclusively. This is critical because transfer of stem cells into patients will require that the cells have been
grown without exposure to non- human cells and proteins.

Several of the UCSF studies have achieved significant laboratory milestones and are now waiting to move into clinical
trials. With the help of Mr. Cohen, the new core facility will be one of the only facilities able to grow and study
embryonic and adult stem cells as well as other cellular products under conditions that can be used in patients with a
variety of diseases. The new core facility will also help further the research of treatments for diabetes and the
development of potential vaccines for various cancers including colon, prostate and brain tumors. Stem cell research
and therapies for heart disease and HIV also are poised to enter clinical trials after further development in the core
facility. "The continued growth of private funding resources provides the support we need to continue the most
promising Stem Cell research," says Dr. Bluestone. "We couldn't be more pleased with the recognition we're receiving
and the practical emphasis Mr. Cohen provides. The United States is a leading source of breakthrough developments in
stem cell research. Private donations are a major source of funding that will keep us on pace."

Mr. Cohen focuses his philanthropy on improving the welfare of children through local, national and international
programs. He has committed millions of dollars to support therapeutic programs for California children living with
cancer, expansion of vision care programs for third-world children, and educational programs focused on the arts and
social sciences. His grants are monitored with evaluation protocols that gauge their effectiveness and offer
operational options that help these programs adapt to changing program environments. More information is available at
www.moulicohen.com.

To learn more about UCSF's Developmental and Stem Cell Biology Program visit
http://www.ucsf.edu/research/stem_cells.html or contact Erik Rausch at 415/502-1758 or [log in to unmask]

CONTACT:

Nancy Ryan
818.749.7478

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com

Source: University of California, San Francisco

SOURCE: eReleases / PR Newswire / Yahoo News (press release)
http://biz.yahoo.com/prnews/031014/phtu004_1.html

* * *

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn